Dengue is caused by 4 related but distinct flaviviruses, DENV1 – 4, which result in 390 million infections annually, with one-third of the world’s population at risk. Most flaviviruses are transmitted by arthropods, such as mosquitoes and ticks, and are responsible for diseases such as yellow fever, West Nile fever, and Japanese encephalitis. DENV is primarily transmitted by the bite of an infected female Aedes aegypti mosquito, which is endemic to every global region except Europe and Antarctica. Dengue primarily occurs in South and Southeast Asia, Africa, tropical South and Central America, and the Caribbean. In the United States, dengue is a nationally notifiable disease, with 677 cases reported to the Centers for Disease Control and Prevention (CDC) in 2014. It is endemic in Puerto Rico, the US Virgin Islands, and American Samoa. Most US cases result from travel to an endemic area, but locally acquired dengue has been documented...
Dengue and Chikungunya
AUTHOR DISCLOSURE
Dr Lee has disclosed that he was a speaker for Novartis Vaccines. His relationship with them ended in June 2015. Dr Krilov has disclosed that he is site principal investigator for a meningococcal B vaccine trial for Pfizer and that Pfizer provides funding to his institution; site principal investigator for an observational study of respiratory syncytial virus (RSV) infections in preterm infants for AstraZeneca and that AstraZeneca provides funding to his institution; and site principal investigator for a clinical trial of a humanized monoclonal antibody to prevent RSV in high-risk preterm infants for Regeneron. This commentary does not contain discussion of an unapproved/investigative use of a commercial product or device.
Paul J. Lee, Leonard R. Krilov; Dengue and Chikungunya. Pediatr Rev April 2016; 37 (4): 179–181. https://doi.org/10.1542/pir.2015-0172
Download citation file: